12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Herceptin trastuzumab regulatory update

Roche reported in its 1H11 earnings that it submitted an application to EMA for Herceptin trastuzumab as a neoadjuvant therapy for breast cancer. The humanized mAb against

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >